{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:52:44Z","timestamp":1781952764224,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10928-026-10024-z","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:12:18Z","timestamp":1774361538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modeling, Simulation, and Extrapolation to Optimize Pediatric Development Plan: Sarilumab Polyarticular-Course juvenile arthritis Application"],"prefix":"10.1007","volume":"53","author":[{"given":"Christine","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Baret-Cormel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanaja","family":"Kanamaluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"2","key":"10024_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for R (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390\u2013392","journal-title":"J Rheumatol"},{"issue":"1","key":"10024_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00443-8","volume":"18","author":"M Dave","year":"2020","unstructured":"Dave M, Rankin J, Pearce M, Foster HE (2020) Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J 18(1):49. https:\/\/doi.org\/10.1186\/s12969-020-00443-8","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"10024_CR3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3899\/jrheum.120661","volume":"40","author":"LR Harrold","year":"2013","unstructured":"Harrold LR, Salman C, Shoor S, Curtis JR, Asgari MM, Gelfand JM, Wu JJ, Herrinton LJ (2013) Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996\u20132009. J Rheumatol 40(7):1218\u20131225. https:\/\/doi.org\/10.3899\/jrheum.120661","journal-title":"J Rheumatol"},{"key":"10024_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/CLEP.S53168","volume":"6","author":"EJ Oberle","year":"2014","unstructured":"Oberle EJ, Harris JG, Verbsky JW (2014) Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches. Clin Epidemiol 6:379\u2013393. https:\/\/doi.org\/10.2147\/CLEP.S53168","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10024_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F (2014) Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 81(2):112\u2013117. https:\/\/doi.org\/10.1016\/j.jbspin.2013.09.003","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10024_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, Ilowite NT, Khubchandani R, Laxer RM, Lovell DJ, Petty RE, Wallace CA, Wulffraat NM, Pistorio A, Ruperto N, Pediatric Rheumatology International Trials O (2019) Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 46(2):190\u2013197. https:\/\/doi.org\/10.3899\/jrheum.180168","journal-title":"J Rheumatol"},{"issue":"6","key":"10024_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Perez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gamir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation P, Pediatric Rheumatology Collaborative Study G (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110\u20131117. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205351","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10024_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A, Pediatric Rheumatology Collaborative Study G, Pediatric Rheumatology International Trials O (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810\u2013820. https:\/\/doi.org\/10.1056\/NEJMoa0706290","journal-title":"N Engl J Med"},{"issue":"10","key":"10024_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22087","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK, American College of R (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken) 65(10):1551\u20131563. https:\/\/doi.org\/10.1002\/acr.22087","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10024_CR10","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology International Trials O, Pediatric Rheumatology Collaborative Study G (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56(9):3096\u20133106. https:\/\/doi.org\/10.1002\/art.22838","journal-title":"Arthritis Rheum"},{"issue":"9636","key":"10024_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, Paediatric Rheumatology ITO, Pediatric Rheumatology Collaborative Study G (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383\u2013391. https:\/\/doi.org\/10.1016\/S0140-6736(08)60998-8","journal-title":"Lancet"},{"issue":"1\u20132","key":"10024_CR12","first-page":"72","volume":"64","author":"DJ Lovell","year":"2006","unstructured":"Lovell DJ (2006) Update on treatment of arthritis in children: new treatments, new goals. Bull NYU Hosp Jt Dis 64(1\u20132):72\u201376","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"5","key":"10024_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2011-201060","volume":"72","author":"MH Otten","year":"2013","unstructured":"Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW (2013) Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC register. Ann Rheum Dis 72(5):721\u2013727. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201060","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10024_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, Wedderburn LR, Yeung RSM, Martini A (2021) Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol 17(5):257\u2013269. https:\/\/doi.org\/10.1038\/s41584-021-00590-6","journal-title":"Nat Rev Rheumatol"},{"issue":"9563","key":"10024_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369(9563):767\u2013778. https:\/\/doi.org\/10.1016\/S0140-6736(07)60363-8","journal-title":"Lancet"},{"issue":"1","key":"10024_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12969-021-00629-8","volume":"19","author":"LN Zaripova","year":"2021","unstructured":"Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA (2021) Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J 19(1):135. https:\/\/doi.org\/10.1186\/s12969-021-00629-8","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"10024_CR17","doi-asserted-by":"publisher","first-page":"e107886","DOI":"10.1371\/journal.pone.0107886","volume":"9","author":"I Caiello","year":"2014","unstructured":"Caiello I, Minnone G, Holzinger D, Vogl T, Prencipe G, Manzo A, De Benedetti F, Strippoli R (2014) IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. PLoS ONE 9(10):e107886. https:\/\/doi.org\/10.1371\/journal.pone.0107886","journal-title":"PLoS ONE"},{"issue":"6","key":"10024_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16(6):335\u2013345. https:\/\/doi.org\/10.1038\/s41584-020-0419-z","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10024_CR19","first-page":"493","volume":"10","author":"F De Benedetti","year":"1992","unstructured":"De Benedetti F, Robbioni P, Massa M, Viola S, Albani S, Martini A (1992) Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol 10(5):493\u2013498","journal-title":"Clin Exp Rheumatol"},{"key":"10024_CR20","unstructured":"Sanofi-Aventis Kevzara\u00ae (sarilumab) injection, for subcutaneous use [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761037s000lbl.pdf. Accessed 10 January 2025"},{"issue":"8","key":"10024_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/1060028018761599","volume":"52","author":"EG Boyce","year":"2018","unstructured":"Boyce EG, Rogan EL, Vyas D, Prasad N, Mai Y (2018) Sarilumab: review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis. Ann Pharmacother 52(8):780\u2013791. https:\/\/doi.org\/10.1177\/1060028018761599","journal-title":"Ann Pharmacother"},{"key":"10024_CR22","unstructured":"Kevzara Prescribing Information [Internet] (2024) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761037s015lbl.pdf. Accessed 13 November 2025"},{"key":"10024_CR23","unstructured":"Kavzara (2025) Summary of product characteristics (SmPC). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kevzara-epar-product-information_en.pdf. Accessed 13 November 2025"},{"key":"10024_CR24","unstructured":"ClinicalTrials.gov A repeated dose-finding study of sarilumab in children and adolescents with systemic juvenile idiopathic arthritis (SKYPS) [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT02991469. Accessed 05 January 2025"},{"key":"10024_CR25","unstructured":"ClinicalTrials.gov An open-label, ascending, repeated dose-finding study of sarilumab in children and adolescents with polyarticular-course juvenile idiopathic arthritis (pcJIA) [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT02776735. Accessed 05 January 2025"},{"issue":"12","key":"10024_CR26","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/art.41043","volume":"71","author":"LE Schanberg","year":"2019","unstructured":"Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V, Ringold S, Vesely R, Schrandt S, Jaki T, Bili A, Chung JB, De Bono S, Douglass W, Enejosa JV, Kanik KS, Knobe K, Kunder R, Leite-Schnell JC, Suehiro RM, Wong RL, Mieszkalski KL, Marrow LC, Siebenaler K, Fraulo E, Kimura Y (2019) Toward accelerated authorization and access to new medicines for juvenile idiopathic arthritis. Arthritis Rheum 71(12):1976\u20131984. https:\/\/doi.org\/10.1002\/art.41043","journal-title":"Arthritis Rheum"},{"key":"10024_CR27","unstructured":"European Medicines Agency (2025) Reflection paper on the use of extrapolation in the development of medicines for paediatrics [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf. Accessed 13 November"},{"key":"10024_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-3-642-20195-0_11","volume":"205","author":"M Roth-Cline","year":"2011","unstructured":"Roth-Cline M, Gerson J, Bright P, Lee CS, Nelson RM (2011) Ethical considerations in conducting pediatric research. Handb Exp Pharmacol 205:219\u2013244. https:\/\/doi.org\/10.1007\/978-3-642-20195-0_11","journal-title":"Handb Exp Pharmacol"},{"key":"10024_CR29","unstructured":"EMA guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis (2016) https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis-revision-2_en.pdf. Accessed 13 November 2025"},{"key":"10024_CR30","unstructured":"General clinical pharmacology considerations for pediatric studies of drugs, including biological products guidance for industry (2022) FDA. https:\/\/www.fda.gov\/media\/90358\/download. Accessed 13 November 2025"},{"issue":"11","key":"10024_CR31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40262-019-00765-1","volume":"58","author":"C Xu","year":"2019","unstructured":"Xu C, Su Y, Paccaly A, Kanamaluru V (2019) Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis. Clin Pharmacokinet 58(11):1455\u20131467. https:\/\/doi.org\/10.1007\/s40262-019-00765-1","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10024_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/bdd.1952","volume":"37","author":"J Wang","year":"2016","unstructured":"Wang J, Iyer S, Fielder PJ, Davis JD, Deng R (2016) Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Biopharm Drug Dispos 37(2):51\u201365. https:\/\/doi.org\/10.1002\/bdd.1952","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"10024_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000171","volume":"4","author":"VM Savage","year":"2008","unstructured":"Savage VM, Deeds EJ, Fontana W (2008) Sizing up allometric scaling theory. PLoS Comput Biol 4(9):e1000171. https:\/\/doi.org\/10.1371\/journal.pcbi.1000171","journal-title":"PLoS Comput Biol"},{"issue":"8","key":"10024_CR34","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3899\/jrheum.170326","volume":"45","author":"KN Bharucha","year":"2018","unstructured":"Bharucha KN, Brunner HI, Calvo Penades I, Nikishina I, Rubio-Perez N, Oliveira S, Kobusinska K, Schmeling H, Sztajnbok F, Weller-Heinemann F, Zholobova E, Zulian F, Allen R, Chaitow J, Frane J, Wells C, Ruperto N, De Benedetti F, Paediatric Rheumatology International Trials O, the Pediatric Rheumatology Collaborative Study G (2018) Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial. J Rheumatol 45(8):1173\u20131179. https:\/\/doi.org\/10.3899\/jrheum.170326","journal-title":"J Rheumatol"},{"issue":"6","key":"10024_CR35","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, van Adelsberg J, Weinstein SP, Graham NM, Stahl N, Yancopoulos GD, Huizinga TW, van der Heijde D (2015) Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 67(6):1424\u20131437. https:\/\/doi.org\/10.1002\/art.39093","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10024_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR (2017) Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol 69(2):277\u2013290. https:\/\/doi.org\/10.1002\/art.39944","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10024_CR37","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC (2014) Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part A trial. Ann Rheum Dis 73(9):1626\u20131634. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204405","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10024_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.clinthera.2022.01.015","volume":"44","author":"JB Lee","year":"2022","unstructured":"Lee JB, Broadwell A, Fan Y, Hu C, Adedokun OJ, Chakravarty SD, Zhou H, Xu Z, Leu JH (2022) Population Pharmacokinetic and exposure-response model simulations: predicted exposure and efficacy for maintenance doses of intravenous golimumab every 6 or 8 weeks in patients with moderately to severely active rheumatoid arthritis. Clin Ther 44(3):457\u2013464e452. https:\/\/doi.org\/10.1016\/j.clinthera.2022.01.015","journal-title":"Clin Ther"},{"issue":"2","key":"10024_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/jcph.1308","volume":"59","author":"X Li","year":"2019","unstructured":"Li X, Roy A, Murthy B (2019) Population pharmacokinetics and exposure-response relationship of intravenous and subcutaneous abatacept in patients with rheumatoid arthritis. J Clin Pharmacol 59(2):245\u2013257. https:\/\/doi.org\/10.1002\/jcph.1308","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10024_CR40","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s40262-020-00899-7","volume":"59","author":"L Ma","year":"2020","unstructured":"Ma L, Xu C, Paccaly A, Kanamaluru V (2020) Population pharmacokinetic-pharmacodynamic relationships of sarilumab using disease activity score 28-joint C-reactive protein and absolute neutrophil counts in patients with rheumatoid arthritis. Clin Pharmacokinet 59(11):1451\u20131466. https:\/\/doi.org\/10.1007\/s40262-020-00899-7","journal-title":"Clin Pharmacokinet"},{"key":"10024_CR41","unstructured":"De Benedetti FPCI, Nikishina I et al (2024) Sarilumab in polyarticular-course juvenile idiopathic arthritis: dose-finding and one-year interim analysis of a phase 2b, open-label, multicentre study. [Manuscript under preparation]"},{"issue":"2","key":"10024_CR42","first-page":"1","volume":"11","author":"PHJ Lu","year":"2013","unstructured":"Lu PHJ, Keane C et al (2013) PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients. Pediatr Rheumatol 11(2):1\u20132","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"10024_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1586\/ecp.13.1","volume":"6","author":"X Zhang","year":"2013","unstructured":"Zhang X, Morcos PN, Saito T, Terao K (2013) Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol 6(2):123\u2013137. https:\/\/doi.org\/10.1586\/ecp.13.1","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10024_CR44","doi-asserted-by":"crossref","unstructured":"Hossain A, Xu C, Raveendran G, Abdallah H, Baret-Cormel L, Meng Z (2025) Exposure-response modeling of efficacy and safety endpoints of sarilumab in pediatric patients with polyarticular-course juvenile arthritis. Poster presented at American Conference in Pharmacometrics (2025), Colorado USA, [T-078]. https:\/\/acop2025.eventscribe.net\/fsPopup.asp?PosterID=761817&mode=posterInfo. Accessed 25 Nov 2025","DOI":"10.70534\/VZIG8855"},{"key":"10024_CR45","doi-asserted-by":"crossref","unstructured":"Gao Y, Xu C, Shao S, Abdallah H, Macha S, Ahmadi M (2025) population pharmacokinetic analysis to characterize pharmacokinetics of sarilumab in pediatric participants with polyarticular-course juvenile idiopathic arthritis. Poster presented at American Conference in Pharmacometrics (2025), Colorado USA, [T-079]. https:\/\/acop2025.eventscribe.net\/ajaxcalls\/PosterInfo.asp?PosterID=761816. Accessed 25 Nov 2025","DOI":"10.70534\/VLGX6111"},{"issue":"4","key":"10024_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/jcph.826","volume":"57","author":"H Abdallah","year":"2017","unstructured":"Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, Bao M, Rowell L, Burmester GR, Kivitz A (2017) Pharmacokinetic and pharmacodynamic analysis of subcutaneous Tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol 57(4):459\u2013468. https:\/\/doi.org\/10.1002\/jcph.826","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10024_CR47","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/jcph.1797","volume":"61","author":"Y Gandhi","year":"2021","unstructured":"Gandhi Y, Passarell JA, Roy A, Murthy B (2021) Model-based selection and recommendation for subcutaneous abatacept dose in patients with polyarticular juvenile idiopathic arthritis. J Clin Pharmacol 61(5):688\u2013699. https:\/\/doi.org\/10.1002\/jcph.1797","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10024_CR48","doi-asserted-by":"publisher","first-page":"464","DOI":"10.7326\/0003-4819-133-6-200009190-00015","volume":"133","author":"SS Ellenberg","year":"2000","unstructured":"Ellenberg SS, Temple R (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 133(6):464\u2013470. https:\/\/doi.org\/10.7326\/0003-4819-133-6-200009190-00015","journal-title":"Ann Intern Med"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10024-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10024-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10024-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:41:53Z","timestamp":1781952113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-026-10024-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10024"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10024-z","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CX, MZ, YL, LB-C, VK, and ZM are employees of Sanofi and may hold stocks and other ownership interests in the company. FDB received consultancy and unrestricted grants from AbbVie, Pfizer, Sanofi, Roche, Novartis, Sobi, Apollo, and Elixiron. HA is an employee of Regeneron Pharmaceuticals Inc. and may hold stocks and other ownership interests in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}